{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-25-000014","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.533946+00:00","generated_at":"2026-05-24T06:24:04.212204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neurogene posts FY2024 net loss $75.1M, cash $312.4M, NGN-401 gets EMA PRIME, trial updates","bullets":["Cash and marketable securities $312.4M as of Dec 31, 2024; runway into H2 2027 to support NGN-401 registrational trial and pipeline.","R&D expenses $60.9M in FY2024 (up from $44.4M) on higher Rett trial costs and headcount; net loss $75.1M vs $36.3M prior year.","NGN-401 Phase 1/2 trial: dose fixed at 1E15 vg, age range expanded >11 years; received EMA PRIME designation.","Anticipated milestones: regulatory update on registrational plans in H1 2025; additional interim clinical data in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-25-000014","json":"https://secwatch.observer/filing/0001404644-25-000014.json","markdown":"https://secwatch.observer/filing/0001404644-25-000014.md","text":"https://secwatch.observer/filing/0001404644-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/0001404644-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000014/ngne-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:24:04.212204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}